Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
3h
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Novo Nordisk announced further trials of its obesity drug, CagriSema, following unsatisfactory results from a previous phase. A new Phase III trial will assess long-term efficacy, launching on ...
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,” mitigating a raft of health conditions beyond obesity and ...
The Senate confirms Lee Zeldin to lead the E.P.A. The Justice Dept. seeks to have criminal charges dismissed against a former Republican representative. Trump signs Laken Riley Act, a law to make ...
Kennedy once again betrays his ignorance about Medicaid. “The premiums are too high, the deductibles are too high, and everybody’s getting sicker,” he said. But Medicaid has no premiums or ...
Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty The quarter-point reduction marks a step down from the Bank of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback